---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-013513"
form_type: "8-K/A"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:15:00.488335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica corrects private placement terms; raises up to ~$55M for clinical trials

## Summary
- Corrected offering: 4,985,610 shares, 306,506 pre-funded warrants, 5,292,116 common warrants at $3.827/unit.
- Upfront gross proceeds $20.4M; potential $33.1M from warrant exercise for total ~$54M (press release: ~$55M).
- Preliminary cash Dec 31, 2023: $11.2M; net proceeds to fund Phase 2 trials of Auxora in AP and AKI.
- New investors include Deerfield affiliate, Soleus Capital, Stonepine, Aisling; existing Sanderling and Bering participated.
- Tranche A warrants ($5.36) expire Dec 31, 2024 or 30 days after AP topline; Tranche B ($7.15) expire Dec 31, 2026 or after AKI topline.

## SEC filing metadata
- accession: 0001193125-24-013513
- form_type: 8-K/A
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/0001193125-24-013513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/d738337d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-013513
- JSON: https://secwatch.observer/filing/0001193125-24-013513.json
- Plain text: https://secwatch.observer/filing/0001193125-24-013513.txt

## Key facts
- Material Agreements
  CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $20.4 million (effective 2024-01-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $20.4 million
  - Effective: 2024-01-19
  source text: On January 19, 2024, the Company and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/0001193125-24-013513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.